摘要
目的评价如意金黄散治疗静脉炎的有效性和安全性。方法计算机检索Cochrane图书馆、PubMed数据库、Embase数据库、ISI数据库、CBM数据库、CNKI数据库、VIP数据库、万方数据库,纳入如意金黄散对50%硫酸镁对于静脉炎的随机对照试验(RCT)、系统评价(SR)和Meta分析,对纳入的随机对照试验进行方法学质量评价和Meta分析,参考纳入的系统评价和Meta分析结论。结果如意金黄散和50%硫酸镁溶液对于静脉炎治疗共纳入10个RCT。两组治疗静脉炎的总有效率有统计学意义[RR 12.96,95%CI(5.81,28.89)],P<0.000 01;显效率差异有统计学意义[OR 9.11,95%CI(3.98,20.88)],P<0.000 01;如意金黄散治疗72 h对静脉炎的发生率及静脉炎I级皮肤损伤发生率与硫酸镁无统计学差异[RR分别为7.76和0.13,95%CI分别为(0.94,64.19)和(0.02,1.07)],P>0.05。结论如意金黄散可有效地治疗静脉炎,其疗效优于50%硫酸镁,同时无不良反应报道。
OBJECTIVE To evaluate the therapeutic effect and safety of Ruyi Jinhuang Powder for phlebitis. METHODS The Cochrane Library, PubMed database, Embase database, ISI database, CBM database, CNKI database, VIP Database, and Wanfang database were searched. Randomized controlled trials （RCT） , systematic reviews （SR）and meta-analysis of treating phlebitis by Ruyi Jinhuang Powder and 50% magnesium sulfate were included. Methodological quality assessment and meta-analysis of randomized con- trolled trials were carried out, and the conclusions of the included systematic reviews and meta-analyses were referred to. RESULTS Ten RCTs comparing Ruyi Jinhuang Powder and 50% magnesium sulfate for treatment of phlebitis were included into the analysis. The total efficiencies of the two drugs had statistical significance [ RR 12. 96, 95% CI （5.81,28. 89） ,P 〈0. 000 01]. The obvious effec- tive rates were statistically different [ OR 9. 11, 95% CI （3.98, 20. 88） , P 〈 0. 000 01 ]. There was no statistic difference between Ruyi Jinhuang Powder and magnesium sulfate in the incidence of phlebitis and grade I skin injury in the 72 h of treatment [ RR：7.76 and 0. 13, 95 % CI ： （0. 94, 64. 19 ） and （0. 02, 1.07 ） , P 〉 0. 05 ]. CONCLUSION Ruyi Jinhuang Powder is effective for treating phlebitis, the therapeutic effect is better than 50% magnesium sulfate, and no adverse drug reaction has been reported.
出处
《中国药学杂志》
CAS
CSCD
北大核心
2012年第22期1860-1864,共5页
Chinese Pharmaceutical Journal
基金
国家科技支撑计划重点项目(2009BAI76B030218)
关键词
如意金黄散
静脉炎
META分析
循证药学
Ruyi Jinhuang Powder
phlebitis
Meta-analysis
evidence-based pharmacy
